Live
Thermo FisherHow Thermo Fisher’s Glacios 3 aims to broaden access to cryo-EM - R&D WorldThermo FisherLobbying Update: $21,000 of THERMO FISHER SCIENTIFIC INC lobbying was just disclosed - Quiver QuantitativeFierceBiotechTakeda tears up Denali partnership, returning dementia asset amid restructuringFierceBiotechAI model designs new treatment candidate for opioid addiction that cuts cravings in ratsAgilentAgilent CLO Departing With Severance After Less Than 2 Years in Role - Law.comBioPharma DiveHims & Hers says limited data stolen in social engineering attackLonza NewsLonza Group AG stock: What investors should know about its biotech edge now - AD HOC NEWSBioPharma DiveUnder-the-skin Tepezza comparable to infused version in key study, Amgen saysEndpoints NewsProposed FDA budget sets Makary up to boost US biotechFierceBiotechWith Sanofi and Pfizer deals, Novavax bets on ‘amplification strategy’ to drive vaccines engineFierceBiotechUS, UK regulators bolster medical device collaboration while lifting tariffsFierceBiotechZeto’s latest EEG device garners FDA 510(k) clearance for outpatient use
10x Genomics Blog Mar 13, 2026

10X Genomics Experiences Evaluation Revision Amid Mixed Market Signals and Performance Metrics - Markets Mojo

10X Genomics Experiences Evaluation Revision Amid Mixed Market Signals and Performance Metrics - Markets Mojo

Original
Body unavailable. Use the original source.

Directory

59 All